Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis.

Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis.

Show other versions (1)

The prolyl-tRNA synthetase (PRS) is a validated drug target for febrifugine and its synthetic analog halofuginone (HFG) against multiple apicomplexan parasites including Plasmodium falciparum and Toxoplasma gondii. Here, a novel ATP-mimetic centered on 1-(pyridin-4-yl) pyrrolidin-2-one (PPL) scaffol...

Full description

Bibliographic Details
Main Authors: Manickam Yogavel, Alexandre Bougdour, Siddhartha Mishra, Nipun Malhotra, Jyoti Chhibber-Goel, Valeria Bellini, Karl Harlos, Benoît Laleu, Mohamed-Ali Hakimi, Amit Sharma
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-02-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1011124

Internet

https://doi.org/10.1371/journal.ppat.1011124

Similar Items